Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC - Trial NCT06379087
Access comprehensive clinical trial information for NCT06379087 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ji Yongling and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ji Yongling
Zhejiang Cancer Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
Dec 31, 2026
Primary Outcome
1-year EFS Rate
Summary
This study is a single-center, prospective, single-arm exploratory clinical study of
 hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant
 therapy. It is designed for patients with stage II-IIIA non-small cell lung cancer. The
 efficacy and safety of hypofractionated radiotherapy sequential tislelizumab and anlotinib in
 the neoadjuvant and adjuvant treatment of stage II-IIIA non-small cell lung cancer are
 observed. Finally, it provides new evidence-based medical evidence for the perioperative
 treatment of non-small cell lung cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06379087
Non-Device Trial